AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
It also offers ELISA test kits; and chromatography resins under the CaptivA brand.
In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber.
Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.
The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.
Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Country | United States |
IPO Date | Apr 29, 1986 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 1,783 |
CEO | Olivier Loeillot |
Contact Details
Address: Building 1 Waltham, Massachusetts United States | |
Website | https://www.repligen.com |
Stock Details
Ticker Symbol | RGEN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000730272 |
CUSIP Number | 759916109 |
ISIN Number | US7599161095 |
Employer ID | 04-2729386 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Olivier Loeillot | President, Chief Executive Officer & Director |
James R. Bylund | Chief Operating Officer |
Jason K. Garland | Chief Financial Officer & Chief Compliance Officer |
Keith Lee Robinson | Chief Information Officer |
Anthony J. Hunt | Executive Chair |
Kimberly A. Cornwell | Global Head of Legal |
Neil Whitfield | Vice President & Global Head of Sales |
Ralf Kuriyel | Senior Vice President of Research & Development |
Sondra S. Newman | Global Head of Investor Relations |
Teresa Ferragamo | Senior Director of Marketing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 05, 2024 | 4 | Filing |
Nov 22, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 20, 2024 | 4 | Filing |
Nov 18, 2024 | 10-Q | Quarterly Report |
Nov 18, 2024 | 10-Q/A | [Amend] Quarterly Report |
Nov 18, 2024 | 10-Q/A | [Amend] Quarterly Report |
Nov 18, 2024 | 10-K/A | [Amend] Annual Report |
Nov 18, 2024 | 10-Q/A | [Amend] Quarterly Report |